Journal Article |
| Yang X, Leesar M, Ahmed H, Lendel V, Rodriguez G, Mutlu D, Cawich I, Prasad, A, Oglesby M, Marmagkiolis, K, Phillips N, Jouke D, Michalek J, Liu Q, Milner T, McElroy A, Hoyt, T, Feldman MD, Cilingiroglu M. Impact of Ticagrelor and Aspirin versus Clopidogrel and Aspirin in Symptomatic Patients with Peripheral Arterial Disease: Thrombus Burden Assessed by Optical Coherence Tomography Cardiovascular Revascularization 2018 Feb;.
|
| Ramirez AG, Munoz E, Parma DL, Michalek JE, Holden AE, Phillips TD, Pollock BH. Lifestyle and clinical correlates of hepatocellular carcinoma in South Texas: a matched case-control study Clinical Gastroenterology and Hepatology 2017 Mar;3565(17).
|
| Churnin, I, Michalek JE, Seifi A. Association of Resident Duty Hour Restrictions on Mortality of Nervous System Disease and Disorder Journal of Graduate Medical Education 2016 Oct;8(4):576-580.
|
| Carr KR, Rodriguez M, Ottesen A, Michalek J, Son C, Patel V, Jimenez D, Seifi A. Association Between Relative Anemia and Early Functional Recovery After Severe Traumatic Brain Injury (TBI) Journal of Neuro Critical Care 2016 Oct;.
|
| Phipps JE, Hoyt T, Vela D, Wang T, Michalek JE, Buja LM, Jang IK, Milner TE, Feldman MD. Diagnosis of Thin-Capped Fibroatheromas in Intravascular Optical Coherence Tomography Images: Effects of Light Scattering Circulation: Cardiovascular Interventions 2016 Jul;9(7):1-12.
|
| Patel S, Hurez V, Nawrocki ST, Goros M, Michalek JE, Sarantopoulos J, Curiel T, Mahalingam D. Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer Oncotarget 2016 Jul;7(37):59087-59097.
|
| Dengler BA, Mendez-Gomez P, Chavez A, Avila L, Michalek J, Hernandez B, Grandhi R,Seifi A. Safety of Chemical DVT Prophylaxis in Severe Traumatic Brain Injury with Invasive Monitoring Devices Neuro critical care 2016 Jun;:1-9.
|
| Svalina MN, Kikuchi K, Abraham J, Lal S, Davare MA, Settelmeyer TP, Young MC, Peckham JL, Cho YJ, Michalek JE, Hernandez BS, Berlow NE, Jackson M, Guillaume DJ, Selden NR, Bigner DD, Nazemi KJ, Green SC, Corless CL, Gultekin S, Mansoor A, Rubin BP, Woltjer R, Keller C. IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma Scientific Reports 2016 Jun;.
|
| Ha CS, Michalek JE, Elledge R, Kelley KR, Ganapathy S, Su H, Jenkins CA, Agiris A, Swords R, Eng TY, Karnad A, Crownover RL, Swanson GP, Goros M, Pollock BH, Yuan Z. p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study Molecular Oncology 2016 Jan;10(1):148-56.
|
| Simpson CB, Lee CT, Hatcher JL, Michalek JE. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes Laryngoscope 2016 Jan;126(1):118-121.
|
| Landgren, O, Shim, Y, Michalek JE, Costello, R, Burton, D, Ketchum, N, Calvo, K, Caporaso, N, Raveche, E, Middleton, D, Marti, G, Vogt, R. Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance. An Operation Ranch Hand Veteran Cohort Study JAMA Oncology 2015 Sep;:E1-E8.
|
| Strandberg G, Larsson A, Lipcsey M, Michalek JE, Eriksson M. Intraosseous and intravenous administration of antibiotics yields comparable plasma concentrations during experimental septic shock Acta Anaesthesiol Scan 2015 Jan;.
|
| Bartanusz Viktor, Jezova Daniela, Sordo Salvador, Gildea Marianne, Michalek JE, Stewart Ronald M, Corneille Michael G. Diurnal Salivary Cortisol Levels in Acute Trauma Patients at the Surgical-Neurosurgical Intensive Care Unit J Clin Neurosci 2014 Dec;21(12):2150-2154.
|
| Larson, Erik R, Porterfield, John E., Marmol-Velez, Juan, Panday, Manoj, Sagar, Sandeep, Escobedo, Daniel, Michalek JE, Ouyang, Yongjian, Valvano, Jonathan, Pearce, John A, Feldman MD. Admittance to Detect Alterations in Left Ventricular Stroke Volume Heart Rhythm 2014 Nov;11(11):2075-2083.
|
| Shi Q, Hodara V, Meng Q, Voruganti VS, Rice K, Michalek JE, Carmuzzie AG, VandeBerg JL. Early endothelial damage detected by circulating particles in baboons fed a diet high in simple carbohydrates in conjunction with saturated or unsaturated fat Am J Cardiovasc Dis 2014 Oct;4(3):123-132.
|
| Abraham J, Nunez-Alvarez Y, Hettmer S, Carrio E, Chen HI, Nishijo K, Huang ET, Prapjapati SI, Walker RL, Davis S, Rebeles J, Wiebush H, McCleish AT, Hampton ST, Bjornson CR, Brack AS, Wagers AJ, Rando TA, Capecchi MR, Marini FC, Ehler BR, Zarzabal LA, Goros MW, Michalek JE, Meltzer PS, Langenau DM, LeGallo RD, Mansool A, Chen Y, Suelves M, Rubin BP, Keller C. Lineage of origin in rhabdomyscarcoma informs pharmacological response Genes Dev 2014 Jul;25(14):1578-1591.
|
| Kilpadi KL, ElDabaje R, Schmitz JE, Ehler B, Thames TA, Joshi AP, Simmons JW, Michalek JE, Fajardo RJ. Type 2 diabetes is associated with vertebral fractures in a sample of clinic- and hospital-based Latinos J Immigr Minor Health 2014 Jun;16(3):440-449.
|
| Mahalingam D, Malik L, Beeram M, Rodon J, Sankhala K, Mita AC, Benjamin D, Ketchum N, Michalek JE, Tolcher A, Wright J, Sarantopoulos J. Phase II Study Evaluating the Effcacy, Safety, and Pharmacodynamic Correlative Study of Dual Antiangiogenic Inhibition Using Bevaciumab in Combination with Sorafenib in Patients with Advanced Malignant Melanoma Cancer Chemother Pharmacol 2014 May;.
|
| Cohn SM, DeRosa M, Kumar A, Harrison C, Dent DL, Sivam S, McCarthy MJ, Warner SC, Williams S, Michalek JE, Spinella P. Impact of the Age of Transfused Red Blood Cells in the Trauma Population: A Feasibility Study Injury 2014 Mar;45(3):605-611.
|
| Kikuchi, Hettmer S, Aslam MI, Michalek JE, Laub W, Wilky BA, Loeb DM, Rubin BP, Wagers AJ, Keller C. Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma PLos Genet 2014 Jan;10(1).
|
| Rowe J, Patel S, Mazo-Canola M, Parra A, Goros M, Michalek JE, Kelly KR, Weitman SD, Karnad AB. An Evaluation of Elderly Patients (> 70 years old) Enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio Cancer Therapy Research Center from 2009-2011 J Geriatr Oncol 2014 Jan;5(1):65-70.
|
| Hummers LK, Dugowson CE, Dechow FJ, Wise RA, Gregory J, Michalek JE, Yenokyan G, McGready J, Wigley FM. A Multi-Centre, Blinded, Randomized, Placebo-Controlled, Laboratory-Based Study of MQX-503, a Novel Topical Gel Formulation of Nitroglycerine in Patients with Raynaud Phenomenon Ann Rheum Dis 2013 Dec;72(12):1962-1967.
|
| Kikuchi k, Taniguchi E, Chen HI, Svalina MN, Abraham J, Huang ET, Nishijo K, Davis S, Louden C, Zarzabal LA, Recht O, Bajwa A, Berlow N, Suelves M, Perkins SL, Meltzer PS, Mansoor A, Michalek JE, Chen Y, Rubin BP, Keller C. RB1 Loss Modifies but does not Initiate Alveolar Rhabdomyosarcoma Skelet Muscles 2013 Nov;3(1).
|
| Aslam MI, Hettmer S, Abraham J, Latocha D, Soundararajan A, Huang ET, Goros MW, Michalek JE, Wang S, Mansoor A, Druker BJ, Wagers AJ, Tyner JW, Keller C. Dynamic and Nuclear Expression of PDGFRa and IGF-1R in Alveolar Rhabdomyosarcoma Mol Cancer Res 2013 Nov;11(11):1303-1313.
|
| Cohn SM, DeRosa M, McCarthy J, Song J, White C, Louden C, Ehler B, Michalek JE, Landry DW. Characterizing Vasopressin and other Vasoactive Mediators Released During Resuscitation of Truama Patients J Trauma Acute Care Surg 2013 Oct;75(4):620-628.
|
| Xiao Y, Haynes W, Russell IJ, Michalek JE. Elevated serum high-sensitivity c-reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate Rheumatol Int 2013 May;33(5):1259-1264.
|
| Schwartz JA, Olarte KT, Michalek JL, Jandu GS, Michel SL, Bruno VM, Michalek JE. Regulation of copper toxicity by Candida albicans GPA2 Eukaryot Cell 2013 Apr;.
|
| Kikuchi K, Soundararajan A, Zarzabal LA, Weems CR, Nelon LD, Hampton ST, Michalek JE, Rubin BP, Fields AP, Keller C. Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma Oncogene 2013 Jan;32(3):286-295.
|
| Garcia-Dominic O, Trevino RP, Echon RM, Mobley C, Block T, Bizzari A, Michalek JE. Improving Quality of Food Frequency Questionnaire Response in Low-Income Mexican American Children Health Promot Pract 2012 Nov;13(6):763-771.
|
| Husain SA, Maldonado E, Rasch D, Michalek JE, Taylor R, Curzon C, Neish S, Calhoon JH. Total anomalous pulmonary venous connection: factors associated with mortality and recurrent pulmonary venous obstruction Ann Thorac Surg 2012 Sep;94(3):825-831.
|
| Soundararajan A, Abraham J, Nelon LD, Prajapati SI, Zarzabal LA, Michalek JE, McHardy SF, Hawkins DS, Malempati S, Keller C. 18F-FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models Pediatr Blood Cancer 2012 Sep;59(3):485-492.
|
| Cornejo A, Sahar DE, Stephenson SM, Chang S, Nguyen S, Guda T, Wenke JC, Vasquez, A, Michalek JE, Sharma R, Krishnegowda NK, Wang HT. Effect of Adipose Tissue-Derived Osteogenic and Endothelial Cells on Bone Allograft Osteogenesis and Vascularization in Critical-Sized Calvarial Defects Tissue Eng Part A 2012 May;18(15-16):1-10.
|
| Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, Kilcoyne A, Giles FJ, Nelon LD, Carew JS, Ouyang Y, Michalek JE, Pal R, Druker BJ, Rubin BP, Keller C. An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma Biochem Biophys Res Commun 2012 Jan;426:363-368.
|
| Salhanick M, Higgins RA, Olson JD, Michalek JE, Harrison CR, Corneille MG, Stewart RM, Harrison C,Dent DL,. Autotransfusion of Hemothorax Blood In Trauma Patients: Is It the Same as Fresh Whole Blood? Am J Surg 2011 Dec;202(6):817-822.
|
Federal |
| Funding Agency |
NIH/NCI |
| Title |
P30 Cancer Center Support Grant at the University of Texas Health Science Center at San Antonio. |
| Status |
Active |
| Period |
8/2009 - 7/2018 |
| Role |
Co-Investigator |
| Grant Detail |
This is a P30 Cancer Center Support Grant at the University of Texas Health Science Center at San Antonio. This grant provides funding for the conduct of cancer clinical trials, prevention studies and assistance with statistical design and analysis of translational cancer research projects. Specifically, this is for support of the biostatistics and medical informatics core which has the following aims: provide flexible, cost-efficient services to CTRC basic, clinical and translational researchers; provides services to aid in the administration of the CTRC including monitoring and reporting functions for compliance with local and Federal regulatory requirements, quality assurance review, preparation of reports and analyses for administrative meetings; to provide informatics components for the Protocol Review Committee, the Data Safety Monitoring Committee and to provide statistical assistance with the development and conduct of clinical protocol-based research. |
| Funding Agency |
Audie Murphy Mem Vets Hospital |
| Title |
CAP Project 5 (344-19) |
| Status |
Active |
| Period |
6/2016 - 5/2018 |
| Role |
Co-Investigator |
| Grant Detail |
The overarching goals of the STRONG STAR Consortium to Alleviate PTSD (STRONG STAR-CAP) are to improve the psychological and physical health and well-being of Service Members (active duty, National Guard, and Reserve) and Veterans who have deployed in support of OEF/OIF/OND by developing and evaluating the most effective diagnostic, prognostic, preventive, treatment, and rehabilitative strategies for combat-related PTSD and comorbid conditions. The STRONG STAR Consortium to Alleviate PTSD will support projects funded by VA-ORD and DoD. This mobility assignment is funded by the Veterans Administration to support this initiative. |
| Funding Agency |
NIH/NIA |
| Title |
Primary Fibroblast Resiliency as a Predictor of Health and Lifespan in Mice |
| Status |
Active |
| Period |
9/2017 - 5/2018 |
| Role |
Co-Investigator |
| Grant Detail |
There has been considerable effort to understand the relationship between cellular resiliency (largely defined in these studies as stress resistance) and longevity. However, prior studies have largely focused on this relationship within populations of animals; that is, addressing whether modifying longevity has a similar effect on stress resistance (or vice versa). This study expands on these prior studies with 3 innovations: 1) we will demonstrate for the first time whether patterns of resiliency in the cells of individual mice may be predictive of the lifespan or cause of death of an individual mouse. 2) Because we can establish cell lines throughout the life of the animal, we will determine whether these cell resiliency patterns change with age and determine at what age may be the most predictive marker. 3) We will discover whether interventions known to affect aging alter these patterns of cellular resiliency as a means to adapt this assay as a screen for potential novel interventions to extend longevity. |
| Funding Agency |
NIH/NIA |
| Title |
Metformin for Preventing Frailty in High Risk Older |
| Status |
Active |
| Period |
6/2017 - 4/2018 |
| Role |
Consultant |
| Grant Detail |
The research described in this proposal will test a pharmacological intervention that could potentially be used to delay/reduce the development of frailty in older adults. In this initial study we will enroll glucose intolerant subjects, a population which encompasses approximately 1/3rd of older adults and is most likely to benefit from metformin. Because of the enormous costs associated with frailty (both personal and economic), an intervention that prevents or delays frailty, even in a sub-population of older adults, would have a major positive impact in our society. To our knowledge, this research will be the first to study a potential intervention targeted toward central pathogenic processes (inflammation and insulin resistance) involved in the etiology of frailty in humans. |
| Funding Agency |
NIH/NTI |
| Title |
A National Coordinating Center for Trauma Research/The PROspective Observational Vascular Injury Trial |
| Status |
Active |
| Period |
12/2015 - 11/2017 |
| Role |
Consultant |
| Grant Detail |
NTI-NTRR15-11/W81XWH-15-2-0089
The objective of this grant is to establish a prospective, multicenter, observational study through the AAST Multicenter Trials Committee. This study, referred to as PROspective Observational Vascular Injury Trial or PROOVIT, aims to capture key elements of vascular trauma presentation, diagnosis, management, outcomes from leading trauma institutions in the US. |
| Funding Agency |
VA |
| Title |
IPAA for Joel E Michalek(Cadena) |
| Status |
Complete |
| Period |
6/2014 - 5/2016 |
| Role |
Co-Investigator |
| Grant Detail |
Failure to isolate patients with pulmonary tuberculosis as a patient safety issue: Defining the problem and estimating its associated costs
Despite advances in its control and prevention, tuberculosis (TB) is an important patient safety issue in the US. Texas and other three states account for over half of the US cases. Healthcare Associated TB exposure cohorts continue to occur despite implementation of the CDC?s recommendations for infection prevention, causing significant costs for healthcare systems. However, recent data on factors predicting the clinical features of TB cases leading to exposures, and the costs of contact tracings for healthcare systems are not available. This should be researched in order ensure a safe environment for patients. |
| Funding Agency |
Psychological Health and TBI Research Program, Congressionally Directed Medical Research Program |
| Title |
The STRONG STAR Multidisciplinary PTSD Research Consortium |
| Status |
Complete |
| Period |
9/2008 - 8/2015 |
| Role |
Consultant |
| Grant Detail |
This is a multidisciplinary and multi-institutional proposal to establish a PTSD research consortium in San Antonio focused on the development and evaluation of prevention and treatment programs for combat-related PTSD in active-duty military personnel and recently discharged military veterans. |
| Funding Agency |
FDA |
| Title |
Phase 2 Study of TH-302 for the Treatment of Glioblastoma |
| Status |
Complete |
| Period |
8/2014 - 6/2015 |
| Role |
Contributor |
| Grant Detail |
This application attempts to challenge the current clinical paradigm [38] in glioblastoma of uniform treatment for all patients with an anitangiogenic agent to a more individualized treatment regimen based on molecular biomarkers that define the individual tumor?s level of hypoxia, and uses that hypoxia as a target of therapy. This approach is novel, and attempts to refine the potential integration of molecular imaging and biomarker analysis as predictive tools. Moreover, this proposal makes use of a new category of therapeutic; the hypoxia activated pro-drug TH-302, in an attempt to improve survival of an orphan disease with dismal outcomes. |
State |
| Funding Agency |
CTRC |
| Title |
Phase 2 Study of Th-302 for the Treatment of Glioblastoma |
| Status |
Active |
| Period |
7/2017 - 6/2018 |
| Role |
Consultant |
| Grant Detail |
One of the most exciting and promising aspects of modern cancer drug development is the potential to personalize treatments by developing drugs that inhibit specific molecular targets. While this potential has come to fruition somewhat, overall this has been limited [37]. Success stories of personalized cancer treatments include erlotinib for anti?epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors for non small-cell lung cancer with modest improvements in survival, anti?human epidermal growth factor receptor 2 (HER2) for breast cancer, and more recently BRAF inhibitors for patients with melanoma whose tumors carried the V600E BRAF mutation. The key to developing such targeted therapies lies in identifying responsive patient populations and tumor characteristics. Due to the molecular heterogeneity of most tumors, however, this has proven extremely challenging. In this application, we take a novel approach in targeting the metabolic state of the tumor, an approach that has not yet been significantly described in the literature. Just as novel is the pairing of an imaging agent and a therapeutic agent whose uptake mechanisms are identical to identify those patients with the highest probability of response. Finally, we integrate the least invasive and potentially simplest means of identifying these patients, through the use of emerging biomarkers of hypoxia. |
| Funding Agency |
CPRIT |
| Title |
Modulation of Autophagy - Phase II Study |
| Status |
Complete |
| Period |
8/2014 - 8/2015 |
| Role |
Contributor |
| Grant Detail |
This will be a randomized, controlled phase II clinical trial of pts with histological documentation of primary colon or rectal adenocarcinoma with metastases, who have received locally and currently approved standard therapies, excluding RGF. Pts will be randomized to RGF or VOR/HCQ, and crossover will be allowed after first progression on the initial therapy. In the single-arm phase study, VOR/HCQ was given daily in 3-week cycles. In this proposed study, we will give VOR/HCQ daily in 4-week cycles, such that this is comparable to the 4-week cycle of RGF (daily for 3 weeks, 1 week off). |
|
| Funding Agency |
National Center for Adv Translational Science |
| Title |
ISG: Inst for Integration of Med |
| Status |
Active |
| Period |
5/2015 - 4/2018 |
| Role |
Co-Investigator |
| Grant Detail |
The objective of the Biomedical Informatics Program (BMIP) is to transform our clinical and translational research enterprise by providing access to and promoting the use of an interconnected set of data resources and informatics tools. We will re-engineer our informatics infrastructure in order to optimize the development of innovative methods to solve increasingly complex multidisciplinary research problems and to integrate genotypic, phenotypic, clinical, and public health data sources. In doing so, the BMIP will provide a valuable resource that promotes the overall goals of the Institute for Integration of Medicine and Science (IIMS). |
